Vopimetostat-Daraxonrasib Combo ‘Extremely Encouraging’ in Metastatic Pancreatic Cancer
The combination produced responses in 11 of 12 pancreatic cancer patients, and Tango plans a Phase 3 trial later this year.
- On Monday, Tango Therapeutics reported that its experimental drug Vopimetostat, combined with Revolution Medicines' Daraxonrasib, shrank tumors in 11 of 12 patients with previously treated pancreatic ductal adenocarcinoma.
- Investigators enrolled patients whose disease advanced after at least one treatment and who carry both a RAS mutation and a genetic deletion called MTAP, which occurs in approximately 40% of pancreatic cancers.
- Initial trial data showed 92% of patients achieved an objective response, with 90% surviving six months without disease progression, suggesting that blocking the PRMT5 enzyme provides additive benefits.
- Shares of Tango surged as much as 49% in Monday's premarket trading as Mizuho analyst Joseph Catanzaro wrote that the move into first-line treatment hints at a "potentially compelling" regimen.
- The company plans to initiate a Phase 3 trial later this year testing the combination as first-line treatment for MTAP-deleted pancreatic cancer, aiming to provide a chemotherapy-free option.
19 Articles
19 Articles
The Advocate-Messenger
We need to talk more about pancreatic cancer
When most people think about cancer, they think about breast cancer, lung cancer or colon cancer. Far fewer people think about pancreatic cancer. Yet as oncologists caring for patients throughout Central Kentucky, pancreatic cancer is one of the diagnoses we worry about the most. Not because it is the most common cancer we see, but because it is often one of the most difficult to treat. Unlike some cancers that can be found through routine scree…
Vopimetostat-daraxonrasib combo ‘extremely encouraging’ in metastatic pancreatic cancer
A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to a topline data announcement released by one of the agent’s manufacturers.A vast majority of patients with methylthioadenosine phosphorylase (MTAP)-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) responded to treatment with vopimetostat
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
